drugset
drugset / Trial / NCT02170922

Bioavailability of BIBR 1048 MS Tablets in Healthy Subjects With or Without Food

NCT02170922 ↗

Phase 1 Completed 6 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Comparative pharmacokinetics of BIBR 1048 MS solution and tablet with or without food

Timeline

Start
1999-07
Primary completion
1999-08
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown 200 mg Oral

Indications

No indication recorded.